- Home
- CCIF vs GNLX Comparison
CCIF vs GNLX Comparison
Compare CCIF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIF
- GNLX
- Stock Information
- Founded
- CCIF 2011
- GNLX 2001
- Country
- CCIF United States
- GNLX United States
- Employees
- CCIF N/A
- GNLX N/A
- Industry
- CCIF Finance/Investors Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- CCIF Finance
- GNLX Health Care
- Exchange
- CCIF Nasdaq
- GNLX Nasdaq
- Market Cap
- CCIF 113.2M
- GNLX 112.5M
- IPO Year
- CCIF N/A
- GNLX 2023
- Fundamental
- Price
- CCIF $6.43
- GNLX $3.44
- Analyst Decision
- CCIF
- GNLX Strong Buy
- Analyst Count
- CCIF 0
- GNLX 4
- Target Price
- CCIF N/A
- GNLX $17.75
- AVG Volume (30 Days)
- CCIF 76.9K
- GNLX 152.2K
- Earning Date
- CCIF 01-01-0001
- GNLX 08-13-2025
- Dividend Yield
- CCIF 25.90%
- GNLX N/A
- EPS Growth
- CCIF N/A
- GNLX N/A
- EPS
- CCIF N/A
- GNLX N/A
- Revenue
- CCIF N/A
- GNLX N/A
- Revenue This Year
- CCIF N/A
- GNLX N/A
- Revenue Next Year
- CCIF N/A
- GNLX N/A
- P/E Ratio
- CCIF N/A
- GNLX N/A
- Revenue Growth
- CCIF N/A
- GNLX N/A
- 52 Week Low
- CCIF $7.43
- GNLX $1.60
- 52 Week High
- CCIF $10.16
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- CCIF 51.09
- GNLX 65.71
- Support Level
- CCIF $6.38
- GNLX $2.80
- Resistance Level
- CCIF $6.48
- GNLX $3.61
- Average True Range (ATR)
- CCIF 0.11
- GNLX 0.22
- MACD
- CCIF 0.03
- GNLX 0.05
- Stochastic Oscillator
- CCIF 77.94
- GNLX 80.23
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.